

Optimapharm Connect



CTIS: First Optimapharm Experiences - an Interview with Sara Weytjens

In recent years, CTIS has become a major topic of discussion in the field of EU clinical research. The implementation of this system has completely **transformed traditional practices** and had a significant impact on the way trials are conducted.

To gain insights into the first-hand experiences of implementing CTIS, we spoke with **Sara Weytjens**, Vice President of Regulatory and Site Activation at Optimapharm.

In our comprehensive interview, Sara shares practical strategies and best practices for its effective implementation. From streamlining submission processes to enhancing transparency and collaboration, Sara provides **invaluable guidance** for companies seeking to optimize the CTIS experience.

[Read the Interview](#)

QUARTERLY HIGHLIGHTS



128

sites initiated in 21 countries, **1004 patients** screened in Phase II Celiac disease study



14

EU and APAC countries submitted on time for a Phase II study, first regulatory approvals received



1

Phase II Allergic rhinitis study successfully closed (21 sites and 300 patients randomized)



eTMF

Veeva Vault eTMF implementation as our eTMF technology of choice




1

CSR delivered in a Phase IV Atrial fibrillation study (56 active sites with 666 patients)



3

database lock completed – Phase II Prostate cancer, Phase II/III Prostate cancer, and Glioblastoma Medical Device



How does an innovative clinical trial revolutionize the treatment of women with PCOS?

Optimapharm is proud to participate in the [SPIOMET4Health](#) project, a clinical trial specifically designed to reshape PCOS treatment. This project focuses on tackling the syndrome at its root rather than merely relieving its symptoms.

In a scientific paper co-authored by **Juan Vicente Torres**, Optimapharm's Vice President of Biostatistics Services, learn more about how this ongoing phase II clinical trial involving a **randomized, double-blind, placebo-controlled** study is paving the way for progress towards an efficient and secure PCOS treatment.

[Learn more about this study](#)



"SPIOMET4HEALTH project is of great significance for women because if the medication works, it could prevent the development of some co-morbidities associated with PCOS, such as infertility, diabetes, and low self-esteem."

Dr. Lourdes Ibáñez, Pediatric endocrinologist at Hospital Sant Joan de Déu, Spain - Coordinator of the SPIOMET4HEALTH project



CASE STUDY

How we helped rescue
the recruitment in an

**OVARIAN CANCER
STUDY**

Case study: How we rescued recruitment in an Ovarian Cancer study


Are patient recruitment challenges slowing down your trials?

Explore our case study and learn how we helped a global oncology company successfully enrol patients in a Medical Device study for the treatment of **Ovarian Cancer**.

[Explore case study](#)

Learn more about our expertise in Breast Cancer clinical research!

By successfully completing 14 Breast Cancer clinical trials (phases II-IV) in the last 5 years, we contribute to shaping new discoveries that have the potential to lead to treatments and therapies for the 2 million women worldwide affected by breast cancer every year.



OPTIMAPHARM

Breast cancer experience



14 clinical trials in the last 5 years



164 sites in 19 countries



Phase II, III & IV clinical trials

0:24 / 0:31

Are you planning to attend upcoming conferences? Meet with our experts!



In the next months, our experts will be attending leading industry conferences:

- **German Biotechnology Days**, 16-17 April 2024, Berlin, Germany
- **Swiss Biotech Day**, 22-23 April 2024, Basel, Switzerland
- **OCT Europe**, 7-8 May 2024, Barcelona, Spain
- **Knowledge for Growth**, 15-16 May 2024, Antwerp, Belgium

If you are attending, don't miss the opportunity to meet with our experts in person to discuss how we can support your upcoming clinical projects!

Reach out to us and book a meeting with our team members!

[Schedule a meeting](#)



Optimapharm

You received this email because you signed up on our website or communicated with a member of our team. If you wish to refrain from receiving quarterly newsletters from Optimapharm, please unsubscribe. To understand how we use your personal information, please see our [privacy policy](#).

Copyright 2023 Optimapharm. All rights reserved.

[Unsubscribe](#)

